Unknown
Not known, observed, recorded; or reported as unknown by the data contributor.
Exact Synonyms
Not Known
U
UNK
Unknown/Not Stated
Unknown
UNKNOWN
{Unknown}
class Information
ALT_DEFINITION
- A proper value is applicable but not known.
- Not known, not observed, not recorded, or refused. (NCI)
- Not known, not observed, not recorded, or refused.
- Reported as unknown by the data contributor.
code
C17998
Contributing_Source
- ACC/AHA
- CDISC
- CTDC
- DIPG/DMG
- FDA
- GDC
- ICDC
- OORO
- PCDC
- SeroNet
- UCUM
DesignNote
Used for Cancer Activities Coding when cancer activity is not specified.
in_subset
- GCT Histology Table
- CRF2 History and Physical Exam at Diagnosis Table
- ICDC Value Terminology
- HL Authorized Value Terminology
- CDISC SDTM Collected Ethnicity Terminology
- AML Demographics Table
- ALL Survival Characteristics Table
- OS Patient Reported Outcomes Metadata Table
- Device Usage ICSR Terminology
- OS Tumor Assessment Table
- ALL Lab Table
- EWS Secondary Malignant Neoplasm Table
- CDISC CDASH Terminology
- SeroNet Prior Test Result
- EWS Survival Characteristics Table
- CRF4 Treatment Radiation Table
- OS Adverse Event Table
- GCT Biopsy/Surgical Procedures Table
- HL Secondary Malignant Neoplasm Table
- ALL Minimal Residual Disease Table
- GCT Survival Characteristics Table
- CDISC SDTM Ethnic Group Terminology
- Electrophysiological Procedures Terminology
- EWS Molecular Analysis Table
- CRF5 Response Evaluation Time Point Table
- CDISC SDTM Relation to Reference Period Terminology
- CDISC SDTM Race Terminology
- CRF4 Treatment Surgery Table
- EWS Lab Table
- Physical Examination Terminology
- GCT Total Dose Table
- HL Medical History Table
- OS Histology Table
- Clinical Data Interchange Standards Consortium Terminology
- CDISC SDTM Risk Assessment Terminology
- CDISC SEND Terminology
- Appendix 6: Symptoms and Signs Terminology
- CRF2 History and Physical Exam Patient Medical History Table
- CRF2 History and Physical Exam Family Medical History Table
- CRF8 Pathology Review Targeted Genomics Table
- AML Off Protocol Therapy/Study Table
- ALL Radiation Therapy Table
- HL Demographics Table
- AML Disease Characteristics Table
- GCT Adverse Events Table
- AML Survival Characteristics Table
- AML Lab Table
- GCT Disease Characteristics Table
- Observation ICSR Terminology
- EWS Biopsy/Surgical Procedures Table
- ALL Adverse Events Table
- CRF3 Diagnosis MRI Brain Table
- HL Patient Reported Outcomes Metadata Table
- EWS Histology Table
- CDISC SDTM Severity Response Terminology
- ALL Disease Characteristics Table
- ALL Medical History Table
- OS Biopsy/Surgical Procedures Table
- HL Adverse Events Table
- CRF3 Diagnosis Table
- GDC Value Terminology
- HL Lab Table
- CRF3 Diagnosis MR Spectroscopy Table
- CRF4 Treatment Chemotherapy Table
- HL Family Medical History Table
- ALL Authorized Value Terminology
- CRF3 Diagnosis CT Scan Table
- GCT Vitals Table
- UCUM Terminology
- Cardiovascular Mortality During Acute COVID-19 Infection Terminology
- CDISC SDTM Adverse Event Outcome Terminology
- AML Radiation Therapy Table
- CRF3 Diagnosis Hydrocephalus Table
- AML Subject Response Table
- CDISC SDTM Collected Race Terminology
- AML Myeloid Sarcoma Involvement Table
- Appendix 4: COVID-19 Cardiovascular Complications Terminology
- AML Cellular Immunotherapy Table
- CRF3 Diagnosis Biopsy Table
- CRF6 DIPG Imaging Assessment Table
- EWS Radiation Therapy Table
- EWS Demographics Table
- CRF4 Treatment Table
- National Health Interview Survey
- CDISC CDASH Concomitant Medication Dosing Frequency per Interval Terminology
- CDISC SDTM Coronary Vessel Disease Extent Terminology
- ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology
- OS Radiation Therapy Table
- OS Subject Response Table
- AML Total Dose Table
- OS Subject Characteristics Table
- GCT Molecular Analysis Table
- CRF4 Treatment Steroids Table
- Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
- CRF3 Diagnosis CSF Table
- CDISC SDTM Normal Abnormal Response Terminology
- GDC Terminology
- Appendix 5: COVID-19 Noncardiovascular Complications Terminology
- OS Medical History Table
- OS Survival Characteristics Table
- CRF6 DMG Imaging Assessment Table
- SeroNet Authorized Values
- FDA Pharmaceutical Quality/CMC Terminology
- CDISC SDTM Yes No Unknown or Not Applicable Response Terminology
- FDA Individual Case Safety Report Terminology
- CDISC SDTM Terminology
- CDISC SEND Age Estimation Method Response Terminology
- GCT Authorized Value Terminology
- AML Medical History Table
- Appendix 7: Diagnostic Procedures Terminology
- PQ/CMC Organization-Site Identifier Type Terminology
- Occupation ICSR Terminology
- Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission) Terminology
- Adverse Event Outcome ICSR Terminology
- HL Survival Characteristics Table
- Operational Ontology for Radiation Oncology Prostate Cancer Terminology
- OS Demographics Table
- CDISC SDTM Microbiology Susceptibility Testing Result Category Terminology
- CDISC SEND Null Flavor Reason Terminology
- GCT Growing Teratoma Syndrome Table
- Appendix 3: COVID-19 Diagnosis Terminology
- EWS Tumor Assessment Table
- CRF4 Treatment Re-Irradiation Table
- OS Authorized Value Terminology
- Report Source ICSR Terminology
- EWS Stem Cell Transplant Table
- AML Minimal Residual Disease Table
- Appendix 8: Pharmacological Therapy Terminology
- AML Transfusion Medicine Procedures Table
- CDISC Protocol Terminology
- OS Total Dose Table
- Therapies for Supportive Care During COVID-19 Infection Terminology
- AML Function Test Table
- CDISC SDTM Tumor and Lesion Identification Test Result Terminology
- HL Staging Table
- CRF4 Treatment Steroids during Re-Irradiation Table
- Operator of Medical Device ICSR Terminology
- ALL Off Protocol Therapy/Study Table
- CRF5 Response Evaluation Image Evaluation Table
- GCT Cytology Table
- Acute Cardiovascular Complications Related to COVID-19 Infection Terminology
- HL Biopsy/Surgical Procedures Table
- CDISC CDASH Exposure Dosing Frequency per Interval Terminology
- AML Adverse Events Table
- AML Stem Cell Transplant Table
- CRF3 Diagnosis Re-Biopsy Table
- EWS Adverse Events Table
- CRF7 Pathology Review Table
- EWS Authorized Value Terminology
- Location of Event Occurrence ICSR Terminology
- AML Concomitant Medication Table
- HL Radiation Therapy Table
- SeroNet Study Descriptors
- CDISC SDTM Mode of Disease Transmission Terminology
- CDISC SDTM Sex of Individual Terminology
- ACC/AHA COVID-19 Appendix Authorized Values
- CRF4 Treatment Complementary Table
- ICDC Terminology
- OS Vitals Table
- CDISC SDTM Cardiac Procedure Indication Terminology
- GCT Tumor Assessment Table
- Therapies for COVID-19 Terminology
- ALL Stem Cell Transplant Table
- GCT Medical History Table
- CRF3 Diagnosis MRI Spine Table
- Appendix 10: End-of-Life Management Terminology
- ALL Vitals Table
- Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19 Terminology
- CDISC SDTM Frequency Terminology
- EWS Disease Characteristics Table
- AML Molecular Analysis Table
- CRF4 Treatment Steroids during Radiation Table
- EWS Non-Protocol Therapy Table
- GCT Staging Table
- Current Symptoms and Signs: Clinical Symptoms Terminology
- GCT Subject Response Table
- Mechanical Support Terminology
- GCT Patient Reported Outcomes Metadata Table
- SeroNet Research Participant Metadata
- HL Protocol Treatment Modifications Table
- GCT Lab Table
- GCT Demographics Table
- CDISC SDTM Subject Status Response Terminology
- AML Authorized Value Terminology
- CRF1 Registration Table
- GCT Radiation Therapy Table
- EWS Vitals Table
- Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology
- CRF4 Treatment Additional Surgeries Table
- ALL Demographics Table
- OS Lab Table
- OS Molecular Analysis Table
- EWS Subject Response Table
- ALL Molecular Analysis Table
- CDISC SDTM Action Taken with Study Treatment Terminology
- CRF5 Response Evaluation Clinical Evaluation Table
- CTDC Value Terminology
- HL Lesion Characteristics Table
- AML Vitals Table
- CRF3 Diagnosis PET Imaging Table
Is_PCDC_ALL_Authorized_Value_For_Variable
- Laboratory Test Method
- Off Study Reason Code
- Adverse Event Pathogen
- Race
- Subject Received Steroids Within One Month Prior to Diagnosis of Disease Phase
- Adverse Event Severity Grade
- Enrolled in Another Therapeutic Study After Off Study
- Personal Medical History
- Site of Radiation Therapy
- Subject Received Steroids Within One Week Prior to Diagnosis of Disease Phase
- Measurable Residual Disease Sample Source
- Acute Lymphoblastic Leukemia
- Cause of Death Detail
- Molecular Sequence Variation
- Molecular Abnormality Result Indicator
- Traumatic Tap
- Type of Stem Cell Transplant
- Treatment-related Mortality Type
- Disease Phase
- CNS Involvement Status at Leukemia Diagnosis
- Total-Body Irradiation
- Sex
- Measurable Residual Disease Unit
- Cause of Death
- Type of Stem Cell Transplant Conditioning Prior to Transplant
- Stem Cell Transplant Source
- Ethnic Group
- Units for Vital Signs Results
- Avascular Necrosis of the Joint
- Last Known Survival Status with Disease
- Lab Result Unit
- Chromosomal Translocation Analysis
- HLA Match Finding
- Adverse Event Grading System
- Laboratory Specimen Type
- Bulky Mediastinal Mass
- Flow Cytometry Type
- Cause of Death Ranking
- Laboratory Test Category
- Adverse Event Attribution to Product or Procedure
Is_PCDC_AML_Authorized_Value_For_Variable
- Traumatic Tap
- Extramedullary Myeloid Sarcoma Site
- HLA-B Match Finding
- Stem Cell Transplant Source
- Molecular Abnormality
- Type of Stem Cell Transplant
- Myeloid Leukemia Associated with Down Syndrome
- Antineoplastic Agent
- Measurable Residual Disease Unit
- French-American-British Classification
- Preexisting Condition
- Adverse Event
- Adverse Event Attribution to Product or Procedure
- Sex
- Type of Stem Cell Transplant Conditioning Prior to Transplant
- Total Dose Units
- Adverse Event Outcome
- Echocardiogram Result Unit
- Medication Administration Status
- Disease Involvement Site
- Concomitant Agent
- Stem Cell Transplant Donor Relationship
- HLA-DQ Match Finding
- HLA-C Match Finding
- BM Analysis Modality at Response
- Laboratory Test Method
- Cause of Death
- GVHD Organ
- Measurable Residual Disease Molecular Marker
- Total-Body Irradiation
- Laboratory Test Category
- Myeloid Sarcoma
- Intensive Care Unit Admission Status
- Radiation Dose Unit
- Lab Result Unit
- Cause of Death Ranking
- Adverse Event Grading System
- Number of Matched HLAs
- Race
- CNS Involvement Status at Leukemia Diagnosis
- Transfusion Product
- Disease Response
- Adverse Event Pathogen
- Secondary Acute Myeloid Leukemia
- HLA Match Finding
- Ethnic Group
- Type of Cellular Immunotherapy
- ANC Threshold at Response
- Cause of Death Detail
- Transfusion Type
- Off Protocol Therapy or Study Reason Code
- Intervention/Medication Detail
- Adverse Event Medication
- WHO AML Classification of Tumors
- Molecular Sequence Variation Type
- Molecular Abnormality Result Indicator
- Platelet Threshold At Response
- Mixed Phenotype Acute Leukemia
- HLA-A Match Finding
- Specify Molecular Abnormality Analysis Method
- Disease Involvement Detection Method
- Flow Cytometry Type
- Pathogen Confirmation Indicator
- GVHD Acuity
- Response Assessment Category
- Transient Abnormal Myelopoiesis Associated with Down Syndrome
- Laboratory Specimen Type
- HLA-DRB1 Match Finding
- Route of Administration
- Site of Radiation Therapy
- Adverse Event Severity Grade
- Adverse Event Intervention
Is_PCDC_EWS_Authorized_Value_For_Variable
- Joint Involvement
- Specify Molecular Abnormality Analysis Method
- Site within Bone
- Limb Salvage Procedure
- Tumor Classification
- GPOH Performance Status
- Molecular Sequence Variation
- Skip Lesion
- Race
- Karnofsky Performance Status
- Adverse Event Grading System
- Procedure Laterality
- Limb Surgery
- Surgical Margin
- Stem Cell Transplant Source
- Peritoneal Cytology
- Amputation
- Surgical Management of Metastatic Lung Disease
- Radiation Dose Unit
- Units for Vital Signs Results
- Tumor Response System
- Radiation Therapy
- Histology
- Adverse Event Attribution Category
- Pleural Effusion
- Organ Transposition Procedure
- Tumor Findings Specimen Type
- Site of Tumor
- Non-Protocol Therapy Type
- Molecular Abnormality
- Ipsilateral Nodule
- Tumor Identifier Method
- Biopsy
- Lansky Play-Performance Status
- Pleural Cytology
- Extent of Resection
- Location of Second Malignant Neoplasm related to Prior Radiation Field
- Disease Response
- Cause of Death
- Specimen Anatomic Site
- Fracture
- Reconstructive Surgery
- Tumor Volume
- Radiation Therapy Laterality
- Surgical Procedure by Type
- Lab Result Unit
- Non-Protocol Therapy Timing
- Site of Radiation Therapy
- Peritoneal Effusion
- Site of Metastasis
- Cause of Death Ranking
- Localization
- Tumor Findings Laterality
- Lymph Node Involvement
- Type of Stem Cell Transplant
- Adverse Event Severity Grade
- Ethnic Group
- Sex
- Surgical Management of Metastatic Non-Lung Disease
Is_PCDC_GCT_Authorized_Value_For_Variable
- Histology
- Source of Institutional or Central Histological Assessment
- Surgical Procedure by Type
- International Germ Cell Consensus Risk Classification
- Response Assessment Category
- Sex
- Disease Involvement Detection Method
- Mature Glial Implant
- Disease Response
- Patient Reported Outcome Measures
- Units for Vital Signs Results
- Race
- Ethnic Group
- Adverse Event Attribution to Product or Procedure
- Karyotype Status
- Tumor Response System
- Site of Tumor
- Staging System
- Lab Result Unit
- Nodal Site
- Radiation Therapy
- Response Assessment Method
- Laboratory Test Category
- Specify Molecular Abnormality Analysis Method
- Tumor Identifier Method
- Growing Teratoma Syndrome Treatment
- Procedure Laterality
- Adverse Event
- Molecular Sequence Variation
- Molecular Abnormality
- Radiation Dose Unit
- Numeric Histology Result Unit
- Neoplasm Stage
- Laboratory Test Method
- Somatic-Type Malignancy
- Personal Medical History
- Surgical Margins Status
- Adverse Event Outcome
- Tumor Classification
- Site of Radiation Therapy
- Laterality
- Gonadal Dysgenesis
- Malignant Germ Cell International Collaborative Risk Classification
- Adverse Event Severity Grade
- Laboratory Specimen Type
- Malignant Cell
- Cause of Death
- Histologic Grade
- Regional Lymph Node Involvement
- Cytology Specimen Type
- Radiation Boost
- Surgical Site
- Dosage Form Unit
Is_Value_For_GDC_Property
- Read Group Per Sequence G/C Content Quality Control Indicator
- Histology ICD-O Morphology Code
- Children's Oncology Group Renal Cancer Staging System
- Dysplasia
- Pharmacologic Substance
- Histone Variant
- Esophageal Columnar Mucosa Goblet Cell Indicator
- Smoking Status
- Normal and Tumor Sample Distance
- Children's Oncology Group Liver Tumor Staging System
- Therapeutic Agent Level Achieved Indicator
- Comorbidity
- International Germ Cell Consensus Risk Classification
- ChIP-Seq Antibody Name
- Tumor Shape Observed Descriptor
- IRS Clinical Grouping System
- Read Group Per Base N Content Quality Control Indicator
- Read Group Kmer Content Quality Control Indicator
- Is Individual Lost to Follow-Up
- Passive Smoke Exposure
- Hepatitis Serology
- Bone Marrow Malignant Cell Indicator
- UICC Pathologic N Category
- Read Group Basic Statistics Quality Control Indicator
- Metastatic Diagnosis
- Mitosis-Karyorrhexis Index
- Ann Arbor Extranodal Involvement Indicator
- Transglottic Extension of Laryngeal Tumor
- Read Group Sequence Duplication Levels Quality Control Indicator
- Zygosity
- Esophageal Columnar Metaplasia Indicator
- ECOG Performance Status
- Diabetes Therapy
- UICC Pathologic Stage
- International Neuroblastoma Pathology Classification
- Hormone Replacement Therapy
- Risk Factors for HIV Infection
- Vascular Invasion Assessment
- Karnofsky Performance Status
- Gastroesophageal Junction Involvement Indicator
- Risk Factor Treatment Indicator
- Ovarian Capsule Status
- Progression or Recurrence Type
- AJCC v8 Pathologic N Category
- Vital Status
- Burkitt Lymphoma Clinical Variant Indicator
- Tissue Sample
- Genetic Variant Origin Indicator
- UICC Staging System Manual
- Therapeutic Effect Indicator
- International Neuroblastoma Staging System
- Ishak Score
- Comorbidity Diagnostic Method
- International Neuroblastoma Risk Group Staging System
- Intervention or Procedure
- UICC Pathologic M Category
- Tumor Regression Grade
- Hormonal Contraception
- Disease Involvement Site
- Pregnancy Outcome
- Hepatitis Sustained Virologic Response
- What is the First Presenting Symptom Related to Disease
- Lymph Node by Anatomic Site
- Tumor Classification
- Anaplasia Indicator
- Risk Factor
- Chromosomal Translocation
- Non-nodal Regional Disease Indicator
- Molecular Analysis
- Chromosome
- ICD-O-3 Morphology Term Diagnosis Question
- Family Cancer History Relative Primary Diagnosis Question
- Drinking Status
- Premature Birth Indicator
- Ovarian Surface Involvement Indicator
- Children's Oncology Group Neuroblastoma Risk Group Staging System
- Current Smoking Frequency
- Enneking Surgical Grade
- IRS Clinical Staging System
- Perineural Invasion Assessment
- AJCC v8 Pathologic Stage
- UICC Clinical T Category
- Columnar Mucosa Indicator
- ChIP-Seq Target Name
- Genotype Match Indicator for Normal/Tumor Matched Tissue Samples
- Primary Site of Disease
- Biospecimen Type
- Therapeutic Oxygen Use Indicator
- Histological Progression Type
- Gender
- Is Lymphatic Invasion Present
- Ann Arbor Clinical Stage
- Diagnosis Pathologically Confirmed Indicator
- Time Between Waking and First Smoke
- UICC Clinical N Category
- Alcoholic Beverage
- AJCC v8 Clinical Stage
- Reflux Treatment Type Indicator
- Read Group Sequence Length Distribution Quality Control Indicator
- Menopause Status
- Ethnic Group
- Disease or Disorder
- Hysterectomy
- Residual Disease
- Biospecimen Collection Method
- Specimen Anatomic Site
- Hysterectomy Margins Involved Indicator
- Radiosensitizing Agent Used Indicator
- Normal or Tumor Sample Pathology Indicator
- Exposure Duration
- Histone
- AJCC v8 Pathologic T Category
- European LeukemiaNet Risk Classification
- Is Macroscopic Satellite Nodule Present
- Outcome of Therapy
- Dose Frequency
- Mismatch Repair Gene Mutation
- Wilms Tumor Histologic Subtype
- Read Group Overrepresented Sequences Quality Control Indicator
- Enneking Metastasis
- Initial Neoplastic Disease Extent Indicator
- Tissue or Organ of Origin
- Pregnant at Diagnosis Indicator
- Extrathyroid Extent Indicator
- Metaplasia Indicator
- UICC Clinical Stage
- Site of Resection or Biopsy
- Enneking Tumor Type
- Concurrent Chemoradiation
- Ploidy
- Race
- Exposure Source Indicator
- Read Group Per Sequence Quality Score Indicator
- Information Source for Cause of Death
- Antigen
- FIGO Stage
- Disease Response
- Prior Therapy
- Ann Arbor B Symptoms Indicator
- Anaplasia Descriptor
- Biospecimen Laterality
- Supratentorial Tumor Site
- Disease Grade Qualifier
- AJCC v8 Clinical T Category
- Dysplasia Degree
- What is the Hormonal Contraceptive Use Status
- International Neuroblastoma Pathology Classification Histologic Group
- AJCC v8 Pathologic M Category
- Alcohol Use History
- Reason Treatment Not Administered
- Micrometastasis Present Indicator
- Immunosuppressant
- Enneking Staging System
- Children's Oncology Group Retinoblastoma Risk Group Staging System
- Family Cancer History
- Non-nodal Tumor Deposits Indicator
- WHO Central Nervous System Grade
- UICC Pathologic T Category
- Smoke Exposure
- Performed Procedure
- UICC Clinical M Category
- Lymph Node Involvement
- Molecular Sequence Variation Type
- Surgical Margins Status
- Read Group Per Base Sequence Quality Indicator
- Laboratory Procedure
- Ann Arbor Pathologic Stage
- Peritoneal Cytology
- International Staging System Stage
- Progressive or Recurrent Disease Indicator
- Diagnostic Method
- AJCC Cancer Staging Manual
- Esophageal Columnar Dysplasia Degree
- Comorbid Condition
- Tumor Focality
- Target Capture Kit Identifier
- Number of Peripancreatic Lymph Nodes Positive
- Largest Diameter of Extrapelvic Peritoneal Metastasis
- Restriction Endonuclease
- AJCC v8 Clinical N Category
- Read Group Per Base Sequence Content Quality Control Indicator
- Secondhand Smoke Exposure as a Child
- Fusion Gene Downstream Gene Symbol
- Progressive or Recurrent Disease Anatomic Site
- Laboratory Specimen Type
- Extracapsular Extension Present Indicator
- Localized Neoplasm
- Cause of Death
- Vascular Invasion Descriptor
- Unit for Functional Test Results
- Imaging Finding
- AJCC v8 Clinical M Category
- Laboratory Test Result
- Preservation Procedure
- Read Group Adapter Content Quality Control Indicator
- Relationship Type
- Medulloblastoma Molecular Subtypes
- Molecular Test Analyte Type
- Therapeutic Effect
- First Variant Gene Symbol
- WHO Neuroendocrine Tumor Grade
- Therapeutic Procedure
- Intent To Treat
- Laterality
- Instrument Model
- Child-Pugh Clinical Classification
- Highly Active Antiretroviral Therapy
- Read Group Per Tile Sequence Quality Indicator
- Family Cancer History Relative Gender Question
- Targeted Anatomic Site
Legacy Concept Name
Unknown
Maps_To
- unknown
- Unknown
Preferred_Name
Unknown
Semantic_Type
Idea or Concept
UMLS_CUI
C0439673
Use_For
Nonspecific
class Relations
Subclass of